Today ABG Sundal Collier sponsored research initiates coverage of Ascelia Pharma. Read the full report here!
Improving cancer contrast
Ascelia Pharma is a Swedish biopharma company listed on the Nasdaq Stockholm main market since March 2019. The company is focused on the development of a novel non-gadolinium based MRI contrast agent for the detection of liver metastases in cancer patients with impaired kidney function. The product Orviglance has successfully completed clinical Ph 3 (SPARKLE) in 2024 and is now in preparations towards submission of a NDA to the US FDA by mid'25. The second pipeline candidate Oncoral (novel chemotherapy formulation for gastric cancer) completed Ph 1 successfully and is Ph 2-ready.
